Stanford ADRC · SPHERE Research Data Hub

Accelerating Alzheimer's Research Through Open Science

The Stanford Alzheimer's Disease Research Center (ADRC) is part of a nationwide network of NIH-designated Centers of Excellence. Explore our SPHERE datasets — no IRB amendment or approval required. A Data Use Agreement applies.

Citing SPHERE: if you use these data, please cite the Stanford ADRC SPHERE data portal and acknowledge NIH/NIA grant P30AG066515.

644
Study Participants
9
Data Modalities
206K+
Total Features
290
Healthy Controls
9
Diagnosis Groups
Latest Announcements
New
Data Release
SPHERE Dataset Now Publicly Available

We are pleased to announce the public release of SPHERE (a proprietary privacy-preserving synthetic data generation method developed at Stanford) — a fully synthetic version of the Stanford ADRC cohort. Spanning 644 participants across demographics, cognitive assessments, imaging PET & cortical thickness, whole-genome sequencing (AD-associated SNPs), PBMC scRNA-seq (cell-type pseudo-bulk), and CSF/plasma SomaScan proteomics, SPHERE is available with no IRB amendment or data-use request and approval required. A Data Use Agreement applies.

Documentation

Study Documentation & Data Types

Deep phenotyping across multiple biological data types from longitudinal volunteers with and without cognitive impairment. NIH/NIA grant P30AG066515.

Study Overview

The Iqbal Farrukh and Asad Jamal Stanford ADRC is part of a nationwide network of NIA-designated Centers of Excellence. Its mission is to facilitate multidisciplinary research on Alzheimer's disease and the Lewy body (LB) spectrum of cognitive impairment through deep phenotyping — integrating clinical, neuropsychological, imaging, genomic, proteomic, and neuropathological data from the same individuals followed over time.

Healthy adults serve as a comparison population and as a preclinical population for studying mechanisms of cognitive aging and clinical transition. People with Parkinson's disease without cognitive impairment serve as at-risk comparators for LB-spectrum cognitive impairment. Together these groups enable unique parallel study of AD and LB disorders, providing insights into pathogenesis, preclinical diagnosis, transitions, and therapeutic approaches.

644
ADRC participants
80%
Brain donation consent
7
Research cores
2015
Initial funding (P50)
Research Cores (P30AG066515)
Administrative Core
Coordinates ADRC infrastructure, development projects, and contributions to national repositories (NACC, NCRAD, NIAGADS).
Clinical Core
Enrolls participants; annual neurological exams, neuropsychological testing, and consensus diagnoses using CDR and NACC UDS procedures.
Biomarker Core
Fluid biospecimens (plasma, CSF), whole genome sequencing, immune cell profiling, and plasma/CSF proteomics (SomaScan v4.1).
Imaging Core
Structural MRI (T1, FLAIR), amyloid PET (Florbetaben), tau PET, FDG-PET; processed FreeSurfer outputs and regional SUVRs.
Neuropathology Core
Brain autopsies; well-characterized tissues; quantitative molecular data from high-content imaging; fibroblast cell lines.
Data Management & Statistics
REDCap database; research datasets; biostatistical consultation; bioinformatics and AI tools for big data research.

Cohort Design

Community-dwelling adults from Santa Clara and San Mateo counties (primary catchment, ~2.7M residents), with emphasis on Hispanic/Latino older adults who are underrepresented in AD research. Participants undergo annual comprehensive assessments and are followed longitudinally.

Participant Groups
Healthy Controls (HC)~45%
Mild Cognitive Impairment~20%
Alzheimer's Disease~12%
Parkinson's Disease / PD-MCI~17%
Lewy Body Disease / PDD~5%
Annual Assessment Protocol
Neurological exam and full cognitive battery
Annual blood draw (PBMCs, plasma, DNA)
MRI (T1, FLAIR) and amyloid/tau PET imaging
CSF lumbar puncture every 3 years (consenting)
Brain donation at autopsy (80% consent rate)
Inclusion & Diagnosis
Adults aged 50+ from the Bay Area. Consensus diagnoses are assigned using Clinical Dementia Rating (CDR) scale and NACC Uniform Data Set procedures by board-certified neurologists and neuropsychologists. Biomarker classification follows the NIA-AA A-T-N framework (CSF Aβ42/Aβ40 ratio, amyloid PET, hippocampal volume).

Available Data Types

All SPHERE data modalities are available with no IRB amendment or data-use request and approval required. A Data Use Agreement applies. Data are fully synthetic; no individual's real information is exposed.

Clinical
Cognitive Scores
NACC UDS C2/B4 assessments: MoCA (c2_mocatots), CDR Global (b4_cdrglob), CDR Sum of Boxes, Trail Making A/B, Digit Span Backward, Animals, MINT, Craft Story. Longitudinal data across multiple visits.
Imaging
Imaging Phenotypes
Amyloid PET regional intensities (amy_*), tau PET regional intensities (tau_*), and FreeSurfer cortical thickness (entorhinal, superiorfrontal, inferiorparietal, inferiortemporal, precuneus).
Genomics
Whole Genome Sequencing
Derived from short-read (MGI, ~30×) and long-read nanopore whole-genome sequencing. The SPHERE release includes only AD-associated SNPs and APOE genotype — not the whole genome, structural variants, or genome-wide variant calls. Full WGS data are deposited at NIAGADS.
Single-cell
PBMC scRNAseq
Derived from single-cell RNA sequencing of peripheral blood mononuclear cells. The SPHERE release provides cell-type-specific pseudo-bulk gene expression (one aggregated value per gene per cell type per participant) — not single-cell-resolution counts. Collected annually.
Proteomics
CSF Proteomics
SomaScan (Somalogic) 5,284 aptamers from CSF collected every 3 years via lumbar puncture. AD-relevant targets include APOE, CLU, NEFL, GFAP, IL-6, TNF, BDNF, APP. Values are in relative fluorescence units (RFU).
Proteomics
Plasma Proteomics
SomaScan (Somalogic) 6,900 aptamers plus targeted blood biomarkers: PTAU217, GFAP, NFL. Annual blood draws from all participants.

Publications

Selected peer-reviewed publications acknowledging NIH/NIA grant P30AG066515 (the Stanford ADRC), grouped by year. The full list of 615 publications can be found on PubMed →.

2026
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence
Piyadasa H, Oberlton B, Ribi M, et al. · Cancer cell 2026 · PMID:41386224
Molecular signatures of resilience to Alzheimer's disease in neocortical layer 4 neurons
Dharshini SAP, Sanz-Ros J, Pan J, et al. · Nature communications 2026 · PMID:41620473
White matter micro- and macrostructure brain charts for the human lifespan
Kim ME, Gao C, Ramadass K, et al. · Nature 2026 · PMID:42129567
Long-Term Effect of Acetylcholinesterase Inhibitors on Behavioral and Psychological Symptoms of Dementia
Zuliani G, Boscolo Bragadin F, Romagnoli T, et al. · International journal of geriatric psychiatry 2026 · PMID:41569242
Dark and camouflaged genomic regions remain challenging in CHM13
Wadsworth ME, Page ML, Heberle BA, et al. · Scientific reports 2026 · PMID:41526367
2025
Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease
van Olst L, Simonton B, Edwards AJ, et al. · Nature medicine 2025 · PMID:40050704
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
Imam F, Saloner R, Vogel JW, et al. · Nature medicine 2025 · PMID:40665048
A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease
Oh HS, Urey DY, Karlsson L, et al. · Nature medicine 2025 · PMID:40164724
Plasma proteomics links brain and immune system aging with healthspan and longevity
Oh HS, Le Guen Y, Rappoport N, et al. · Nature medicine 2025 · PMID:40634782
Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum
Ali M, Timsina J, Western D, et al. · Neuron 2025 · PMID:40088886
2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Simuni T, Chahine LM, Poston K, et al. · The Lancet. Neurology 2024 · PMID:38267190
APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia
Haney MS, Pálovics R, Munson CN, et al. · Nature 2024 · PMID:38480892
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies
Minhas PS, Jones JR, Latif-Hernandez A, et al. · Science (New York, N.Y.) 2024 · PMID:39172838
Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease
Zhou X, Shen X, Johnson JS, et al. · Cell host & microbe 2024 · PMID:38479397
AI-based differential diagnosis of dementia etiologies on multimodal data
Xue C, Kowshik SS, Lteif D, et al. · Nature medicine 2024 · PMID:38965435
2023
Organ aging signatures in the plasma proteome track health and disease
Oh HS, Rutledge J, Nachun D, et al. · Nature 2023 · PMID:38057571
Representativeness of samples enrolled in Alzheimer's disease research centers
Arce Rentería M, Mobley TM, Evangelista ND, et al. · Alzheimer's & dementia (Amsterdam, Netherlands) 2023 · PMID:37287650
The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase
Medoh UN, Hims A, Chen JY, et al. · Science (New York, N.Y.) 2023 · PMID:37708259
Lifelong restructuring of 3D genome architecture in cerebellar granule cells
Tan L, Shi J, Moghadami S, et al. · Science (New York, N.Y.) 2023 · PMID:37676945
NREM sleep as a novel protective cognitive reserve factor in the face of Alzheimer's disease pathology
Zavecz Z, Shah VD, Murillo OG, et al. · BMC medicine 2023 · PMID:37138290
2022
A human brain vascular atlas reveals diverse mediators of Alzheimer's risk
Yang AC, Vest RT, Kern F, et al. · Nature 2022 · PMID:35165441
Measuring biological age using omics data
Rutledge J, Oh H, Wyss-Coray T · Nature reviews. Genetics 2022 · PMID:35715611
Multimodal deep learning for Alzheimer's disease dementia assessment
Qiu S, Miller MI, Joshi PS, et al. · Nature communications 2022 · PMID:35725739
Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease
Otero-Garcia M, Mahajani SU, Wakhloo D, et al. · Neuron 2022 · PMID:35882228
Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment
Piehl N, van Olst L, Ramakrishnan A, et al. · Cell 2022 · PMID:36516855
2021
Dysregulation of brain and choroid plexus cell types in severe COVID-19
Yang AC, Kern F, Losada PM, et al. · Nature 2021 · PMID:34153974
An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging
Sayed N, Huang Y, Nguyen K, et al. · Nature aging 2021 · PMID:34888528
Restoring metabolism of myeloid cells reverses cognitive decline in ageing
Minhas PS, Latif-Hernandez A, McReynolds MR, et al. · Nature 2021 · PMID:33473210
Exercise plasma boosts memory and dampens brain inflammation via clusterin
De Miguel Z, Khoury N, Betley MJ, et al. · Nature 2021 · PMID:34880498
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis
Kunkle BW, Schmidt M, Klein HU, et al. · JAMA neurology 2021 · PMID:33074286
Data Availability

Explore What Data Is Available

Each row represents one SPHERE data modality. Colored bars indicate which participants have SPHERE data available. Use the filters below to narrow your cohort.

Filter Participants
Narrow the participant pool. The availability chart and match count update instantly.
Required data types (must have ALL selected):
644
participants match your criteria
HC: 290 AD: 79 Female: 346 Male: 351
Data Availability by Participant
Each column represents one participant, sorted by diagnosis (HC → MCI → AD → PD → other). The top strip shows diagnosis; filled bars indicate available data for each modality.
Diagnosis
Cognitive scores
Blood biomarkers
Amyloid PET
Tau PET
Whole genome seq.
PBMC scRNAseq
CSF proteomics
Plasma proteomics
All samples
Diagnosis strip:
HC
MCI
AD
PD
PDMCI
PDD
LBD
Other
Modalities:
Cognitive scores
Blood biomarkers
Amyloid PET
Tau PET
Whole genome seq.
PBMC scRNAseq
CSF proteomics
Plasma proteomics
All samples
Available Dataset Summary
Cognitive Scores
634 participants
HC286
MCI127
AD78
Blood Biomarkers
618 participants
HC278
MCI120
AD72
Imaging Phenotypes
304 participants
HC131
MCI68
AD37
Whole Genome Seq.
396 participants
HC182
MCI61
AD44
PBMC scRNAseq
310 participants
HC153
MCI46
AD35
CSF Proteomics
142 participants
HC85
MCI15
AD20
Plasma Proteomics
422 participants
HC194
MCI62
AD51
SPHERE Data Explorer

Explore SPHERE Datasets

Browse SPHERE data across all modalities. Filter by diagnosis and sex. Download any subset as CSV.

Key Variables by Diagnosis Group
Boxes = IQR · line = median · Colored by diagnosis group
Data Table
SPHERE Visualization
Interactive 3-D view of the SPHERE synthetic dataset — explore modality structure and how each synthetic twin is placed relative to the real cohort.
Open full screen

SPHERE AI Agent

Ask the SPHERE AI agent to explore, query and analyze SPHERE ADRC data. Python runs in your browser via Pyodide — no data leaves this page.

Get started with SPHERE

Sign in to run the SPHERE AI Agent. New accounts get $10 in free credits to explore, while our launch pool lasts.

or
🔒
Your API key is stored only in this browser session and never sent to Stanford servers. All Python computation runs locally via Pyodide (WebAssembly).
← Portal Ready
Ask me about the SPHERE ADRC data Click an example below, or type your own question:
Extract female participants over 75 with their diagnosis, cognitive scores and plasma proteomics, and give me a download link. What datasets are available and how many participants does each have? What cognitive and biomarker variables are available? Describe their meaning and typical ranges. What is the age and diagnosis breakdown of the ADRC cohort? Show me the distribution of amyloid PET centiloid scores by diagnosis group.
Results appear here Figures and output SPHERE AI generates will appear here.
SPHERE Validation
For each data modality, SPHERE (a proprietary privacy-preserving synthetic data generation method developed at Stanford) data is evaluated on two dimensions: statistical utility (how well the SPHERE data preserves real associations) and privacy protection (how resistant it is to adversarial re-identification). Demographics (sex, race, ethnicity, diagnosis) are encoded numerically so they are synthesized alongside the continuous features. All modalities are synthesized jointly, so cross-modality correlations and between-modality regression coefficients are preserved at the same fidelity as within-modality structure.
About SPHERE

SPHERE (a proprietary privacy-preserving synthetic data generation method developed at Stanford) generates SPHERE datasets that preserve the statistical structure of the real ADRC cohort without exposing any individual's data.

  • Preserves within-modality distributions and diagnostic group contrasts so analyses reflect realistic effect sizes. Demographics (age, sex, race, diagnosis) are embedded in each modality file.
  • Preserves cross-modality correlations — all modalities are synthesized jointly, so between-modality associations and regression coefficients are recovered at the same fidelity as within-modality structure.
  • Spans all modalities: demographics & diagnosis (29 variables), cognitive assessments (73 variables), imaging — amyloid PET (288 ROI features) and tau PET (289 ROI features), whole-genome sequencing — AD-associated SNPs only (167 variables), PBMC scRNA-seq — cell-type pseudo-bulk (193,325 gene × cell-type features), CSF SomaScan proteomics (5,284 aptamers), and plasma SomaScan proteomics + biomarkers (6,900 aptamers).
  • Ideal for methods development, pilot analyses, grant applications, and classroom training.
  • Values do not correspond to any real person — no re-identification is possible.

Data Use Agreement

Access to SPHERE datasets requires acceptance of the Stanford ADRC Data Use Agreement. Please read the agreement below, complete all fields, and confirm your acceptance.

RESEARCH USE ONLY — NO COMMERCIAL USE. This Data is provided solely for non-commercial academic research. Commercial use is strictly prohibited, including training, fine-tuning, or developing any commercial machine-learning, artificial-intelligence, foundation, or generative model, and any for-profit product, service, or algorithm. Commercial use requires a separate written license from Stanford.

Data Use Agreement — Stanford ADRC SPHERE Research Data Hub

This Data Use Agreement ("Agreement") is by and between the Board of Trustees of the Leland Stanford Junior University ("Stanford"), and the Recipient identified below. Dr. Victor Henderson of Stanford is the Stanford Principal Investigator.

Term

This Agreement shall be effective upon the Effective Date. The Term may be extended only by written authorization of both parties.

Stanford Data

Ownership. Stanford retains ownership of the Data and all rights to distribute the Data to other commercial or non-commercial entities.

De-identified Data. All individually identifiable health information has been removed from Data. Data does not include Protected Health Information ("PHI") as defined in 45 C.F.R. Section 160.103. Should Recipient inadvertently receive Data that has not been completely de-identified, or otherwise identifies a subject, Recipient shall notify Stanford immediately and shall follow Stanford's written instructions for handling, which may include return or destruction of the identifiable information.

Recipient Use of Stanford Data

Approved Use. Recipient will use the Data only for the Research Program as authorized under this Agreement during the Term, provided such use does not violate HIPAA regulations or applicable laws. If Recipient desires to use or further disclose any Data for purposes other than the Research Program, Recipient must obtain prior written approval from Stanford.

Non-Commercial Research Only. The Data is provided exclusively for non-commercial academic research and may not be used for any commercial purpose. Prohibited commercial uses include, without limitation: (a) training, fine-tuning, or developing any machine-learning, artificial-intelligence, foundation, or generative model — or any product, dataset, or model weights derived from the Data — for commercial benefit or as a commercial offering; (b) developing, evaluating, or improving any commercial product, service, or algorithm; (c) any for-profit, fee-bearing, or revenue-generating activity; and (d) the sale, licensing, or redistribution of the Data. Any commercial use requires a separate written commercial license from Stanford.

Authorized Users. The Data will be used solely by the Recipient Principal Investigator and Recipient faculty, employees, fellows, and students under the direct supervision of the Recipient Principal Investigator that have a need to use or provide a service in respect of the Data in connection with the Research Program, and whose obligations of use are consistent with the terms of this Agreement.

Further Transfer. Recipient shall permit only Authorized Users to use or receive the Data for the Research Program. Recipient may not share or otherwise disclose the Data to any subcontractors, agents, or any other person who is not an Authorized User without Stanford's prior written approval.

No Re-identification or Contact. Recipient will not attempt to re-identify or otherwise determine the identity of any human subject or other individual who may be the subject of the Data, and will not attempt to contact any such individuals for any purpose. Recipient will immediately notify Stanford if identifiable information is inadvertently received and follow Stanford's reasonable written instructions, which may include return or destruction of such information.

Minimum Necessary. Recipient will not request, access, or use more data than the minimum amount necessary to allow Recipient and its Authorized Users to perform the Research Program.

DOJ Bulk Data Rule. Recipient represents and certifies that it and none of its Authorized Users meet the criteria of a "Covered Person" as defined in 28 CFR Part 202. If at any time Recipient or its Authorized Users meet the definition of a "Covered Person," Recipient shall promptly cease all access to the Data and notify Stanford. Recipient agrees not to share or permit access to the Data by any entity or individual that meets the criteria of a "Covered Person."

Data Security

Safeguards. Recipient will implement and maintain commercially reasonable physical, technical, and organizational security measures to protect the Data against accidental or unlawful loss, destruction, alteration, unauthorized disclosure or access, consistent with Stanford's Minimum Security Standards (minsec.stanford.edu). Recipient shall: maintain accurate logs and records of Data processing; not lease, sell, distribute, or otherwise encumber the Data; and immediately notify Stanford of any investigation, litigation, or dispute relating to Recipient's security or privacy practices as it may relate to Recipient's obligations under this Agreement.

Notice of Data Incidents. Recipient shall without undue delay (within 48 hours of confirmation) notify the Stanford Principal Investigator and Stanford Privacy Contact (https://privacyrequest.stanford.edu) of any security vulnerability, unauthorized access, breach, modification, theft, loss, or destruction of the Data, or any failure to maintain material compliance with this Agreement or applicable law.

Duty to Cooperate and Mitigate. In the event of a data breach or unauthorized use or disclosure of the Data, Recipient will cooperate with Stanford in carrying out mitigation efforts and notifications to government agencies and/or individuals, and will mitigate, to the greatest extent possible, any deleterious effects.

Compliance with Law and Policy. Recipient represents and warrants that its use of the Data will comply with all applicable laws, including international, federal, state and local laws and regulations, and that all relevant institutional policies have been followed, including any required IRB or ethics review.

Audit. Recipient will maintain all documents and records related to this Agreement for four (4) years following the date Recipient no longer has access to or a copy of the Data, subject to inspection and audit by Stanford upon advance notice.

Confidential Information

Definition. "Confidential Information" means any confidential and/or proprietary information related to the performance of this Agreement that is provided by one party to the other and is clearly marked "confidential" or identified as such at the time of disclosure, provided that such information is not publicly known, not independently developed by the Receiving Party, or not available to the public under operation of law.

No Disclosure. The Receiving Party will protect Confidential Information using no less than a reasonable degree of care to prevent unauthorized use or disclosure, the same degree it uses to protect its own confidential information of a like nature.

Term of Confidentiality. The Receiving Party's duty to protect Confidential Information expires three (3) years from receipt.

Compelled Disclosure. If the Receiving Party is required by law to disclose Confidential Information, it will provide the Disclosing Party reasonable notice to allow an opportunity to object and seek appropriate relief.

Certificate of Confidentiality. The Data may be covered under a Certificate of Confidentiality, which must be asserted against compulsory legal demands for identifying information about research participants.

Intellectual Property

Right to Access. Stanford grants Recipient a nonexclusive right to access and use the Data solely for the Research Program during the Term, subject to any third-party rights.

Background Intellectual Property. All Intellectual Property developed outside of this Agreement shall remain the property of its owner.

Foreground Intellectual Property. Stanford shall own Intellectual Property solely conceived by Stanford; Recipient shall own Intellectual Property solely conceived by Recipient; jointly developed Intellectual Property shall be jointly owned.

License to Recipient Intellectual Property. Recipient will provide Stanford a copy of all Recipient Intellectual Property and hereby grants Stanford an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly Recipient Intellectual Property for Stanford's non-commercial research and academic purposes.

No Other Rights. This Agreement does not constitute, grant, nor confer any license under any patents or proprietary interests of Stanford to Recipient, except as explicitly stated herein.

Publication and Acknowledgment

Publication. Before Recipient submits a paper or abstract for publication or otherwise publicly discloses information about its Results, Stanford will have thirty (30) days to review proposed manuscripts and ten (10) days to review proposed abstracts. Stanford may request a delay of up to thirty (30) additional days to protect any potentially identifiable information or Stanford Confidential Information, or to seek patent protection.

Acknowledgment. Recipient agrees to recognize the contribution of Stanford and the Stanford Alzheimer's Disease Research Center (ADRC) as the source of the Data in all written, visual, or oral public disclosures, and shall include the following acknowledgment: "Stanford Alzheimer's Disease Research Center, NIH/NIA grant P30 AG066515."

Reports

Upon Stanford's request, Recipient shall submit a report summarizing Recipient's use of the Data and any Results, to be sent to the Stanford Principal Investigator.

Liability and Indemnification

Liability. In no event shall Stanford be liable for any use by Recipient or Authorized Users of the Data or Results, or for any loss, claim, damage, or liability of any kind arising from or in connection with this Agreement or Recipient's use, handling, transfer, or storage of the Data.

Indemnification. Recipient will indemnify and hold Stanford, its trustees, directors, officers, employees, agents, students, investigators and affiliates harmless against any and all claims, proceedings, demands and liabilities of any kind, including reasonable legal expenses and attorneys' fees, arising out of injury to any person or persons, or out of any damage to property or actual or suspected breach, resulting from Recipient's or Authorized User's willful misconduct or negligent acts or omissions using the Data or Results, except to the extent such claims arise from the willful misconduct or gross negligence of Stanford.

Termination

Termination for Convenience. Either party may terminate this Agreement at any time upon thirty (30) days prior written notice. Within thirty (30) days after termination, Recipient will discontinue all use of the Data and destroy the Data unless otherwise approved by Stanford.

Termination for Cause. Stanford may immediately terminate this Agreement by written notice if Recipient or any Authorized User has defaulted in any material obligation and fails to cure such default within ten (10) days of written notice.

Discontinuation of Use. Upon expiration of this Agreement, Recipient shall immediately discontinue all use of the Data and destroy the Data unless otherwise requested by Stanford.

Governing Law and Dispute Resolution

This Agreement is governed by the laws of the State of California, without reference to its conflict of laws doctrine. Disputes not resolved by mutual agreement may be submitted to binding arbitration under AAA Commercial Arbitration Rules in Palo Alto, California.

General Provisions

Publicity. Neither party will use the name or trademark of the other party in any publicity, advertising, or announcement related to this Agreement without prior written consent.

No Warranties. Data are provided by Stanford AS IS, WITHOUT ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, OR OF NON-INFRINGEMENT.

Amendment. The parties agree to amend this Agreement as necessary to remain in compliance with HIPAA Regulations or any other applicable law, regulation, or institutional policy of Stanford.

Severability. If any provision of this Agreement is found invalid or unenforceable, it shall be deemed severed from this Agreement, but all other provisions shall remain in full force and effect.

Integration. This Agreement supersedes all prior oral and written proposals and communications and sets forth the entire agreement of the parties with respect to the subject matter hereof, and may not be altered or amended except in writing signed by an authorized representative of each party.

Independent Contractors. Stanford and Recipient are independent contractors and neither is an agent, joint venturer, or partner of the other.

Export Controls. Both parties agree to adhere to U.S. export laws and regulations where applicable. Recipient agrees not to disclose Confidential Information that contains technology or technical data identified on any U.S. export control list.

Electronic Copy. The parties agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used.

Assignment. Recipient may not assign this Agreement without Stanford's prior written approval.

Survival. Sections covering Stanford Data, Recipient Use, Data Security, Confidential Information, Intellectual Property, Liability and Indemnification, and Governing Law will survive the termination or expiration of this Agreement.

Force Majeure. Stanford is not liable for any failure to perform as required by this Agreement if caused by circumstances reasonably beyond Stanford's control.

Sign in to download. Get a free key at www.sphereworld.ai — your acceptance and downloads are recorded under your account per the DUA.